Secukinumab for the Treatment of Deficiency of Interleukin 36 Receptor Antagonist in an Adolescent.
暂无分享，去创建一个
[1] H. Nakagawa,et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese study , 2016, The Journal of dermatology.
[2] T. Ruzicka,et al. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status. , 2016, JAMA dermatology.
[3] A. Smahi,et al. First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With Anakinra , 2013, Pediatrics.
[4] E. Alpsoy,et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis , 2012, Archives of Dermatological Research.
[5] Yijun Carrier,et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. , 2011, The Journal of investigative dermatology.
[6] A. Smahi,et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.